| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5080925
Max Phase: Preclinical
Molecular Formula: C26H29N7O
Molecular Weight: 455.57
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1cnc(C#N)c(-c2cn(Cc3ccc4cc(CN5CCC(C)(C)CC5)[nH]c4c3)nn2)c1
Standard InChI: InChI=1S/C26H29N7O/c1-26(2)6-8-32(9-7-26)16-20-11-19-5-4-18(10-23(19)29-20)15-33-17-25(30-31-33)22-12-21(34-3)14-28-24(22)13-27/h4-5,10-12,14,17,29H,6-9,15-16H2,1-3H3
Standard InChI Key: FKEUMAQBZXEVEA-UHFFFAOYSA-N
Associated Targets(Human)
METTL3 Tbio METTL3/METTL14 (156 Activities)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 455.57 | Molecular Weight (Monoisotopic): 455.2434 | AlogP: 4.37 | #Rotatable Bonds: 6 |
| Polar Surface Area: 95.65 | Molecular Species: BASE | HBA: 7 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 8.81 | CX LogP: 4.04 | CX LogD: 2.62 |
| Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.46 | Np Likeness Score: -1.28 |
References
| 1. (2021) Polyheterocyclic compounds as mettl3 inhibitors, |
Source
Source(1):